Leukocyte adhesion deficiency type II
MONDO:0009953Leukocyte adhesion deficiency type II (LAD-II) is a form of LAD characterized by recurrent bacterial infections, severe growth delay and severe intellectual deficit.
Also known as: CDG IIc, CDG syndrome type IIc, CDG-IIc, CDG2C, CDGIIc, LAD-II, LAD2, RHS
2 clinical trials for this condition and its sub-types, 2 tagged with Leukocyte adhesion deficiency type II itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Hope for rare immune disease: new drug enters final testing
Disease control Recruiting nowThis study tests an experimental drug called AVTX-803 in people with leukocyte adhesion deficiency type II (LAD II), a rare genetic condition that weakens the immune system and leads to frequent infections. The trial will compare the drug against a period without treatment to see…
Phase 3 • Sponsor: AUG Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Experimental sugar therapy tested for ultra-rare immune disorder
Disease control Recruiting nowThis phase 3 study is testing the long-term safety and effectiveness of AVTX-803, a form of L-fucose, in people with leukocyte adhesion deficiency type II (LAD II), a rare genetic disorder that weakens the immune system. Only 2 participants who completed a previous study are enro…
Phase 3 • Sponsor: AUG Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC